Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (March 2025)
30 slides from Maia Biotechnology's investor presentation, Mar 21, 2025
Slide 1: MAIA Biotechnology: Telomere Targeting Immunotherapies for Cancer
MAIA BIOTECHNOLOGY TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA March 2025
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS (oi) MAIA NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are “forward-looking statements.’ These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strat
Slide 3: New science for cancer therapy: dual MoA - telomere targeting and immunogenicity
New science for cancer therapy: dual MoA - telomere targeting and immunogenicity. ¢ Lead molecule THIO in clinic; 2nd generation compounds in R&D ¢ Ateganosine approved as nonproprietary (generic) name for THIO Phase 2 trial THIO-101 expansion in 2025: THIO sequenced with CPI in NSCLC. ¢ Unprecedent
Slide 4: Robust Pipeline
ROBUST PIPELINE THIO Telomere Targeting Agent —- Clinical Trials Pipeline Clinical Trial Indication Treatment Status Preclinical Phase Phase 2 Phase 3 Rights THIO> Planned THIO-104 NSCLC 3L CPI Phase 3 r THIO> Ongoing Eta Nscic ais NO Cuenta <= I — —___ rights owned CRC, HCC, THIO > Planned by MAIA.
Slide 5: Mission and Approach
MISSION AND APPROACH (si) MAIA
Slide 6: Oncology Landscape
ONCOLOGY LANDSCAPE Cancer is the most dominant age-related disease a i = mam ‘ Y Population aged >80expectedto — triple by 2050 At age 90: iw... 40% will be million ‘ 44 countries diagnosed, have life 20% will die expectancy of it >80 years 2 : BE Ds A aE _/ Sources: UN (World Social Report, 2023);
Slide 7: Novel Treatment
NOVEL TREATMENT (oi) MAIA THIO (ateganosine) is the only direct telomere targeting anticancer agent in clinical development
Slide 8: Novel Mechanism of Action
NOVEL MECHANISM OF ACTION Ateganosine (6-thio-2'-deoxyguanosine, THIO) Ateganosine has a dual Mechanism of Action: @ Telomere targeting ® Immunogenic effect ateganosine + 3 FDA Orphan Drug Designations: HCC, SCLC, Malignant Gliomas + 4 Rare Pediatric Disease Designation (RPDD): Pediatric Gliomas NYS
Slide 9: THIO-104 NSCLC Trial - Rationale
THIO-104 NSCLC TRIAL - RATIONALE Cycle 4 Cycle 2 * THIO followed by CPI results in 60% complete response * Only 2 cycles of therapy were administered on weeks 1 and 2; no further therapy throughout the study * No recurrence after long-term follow-up « Anticancer immune memory has been induced: no ca
Slide 10: NSCLC Clinical Trials
NSCLC CLINICAL TRIALS (si) MAIA
Slide 11: Trial Design (Ongoing)
TRIAL DESIGN (ONGOING) NYSE American: MAIA AMulticenter, Open-label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Libtayo® (cemiplimab) in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors Efficacy/Safety/Dose Selection Expansion / Regis
Slide 12: Pivotal Trial Design (Planned)
SE 3 PIVOTAL TRI IGN (PLANNED) NYSE America AMulticenter, Open-label, Pivotal Phase 3 Trial Evaluating the Efficacy of THIO (ateganosine) Administered in Sequence with a Checkpoint Inhibitor in NSCLC Patients Who Are Resistant to Checkpoint Inhibitors and Chemotherapy NSCLC SL Ser sets CPI Resistanc
Slide 13: Best Results in Third-Line with the 180mg Dose
BEST RESULTS IN THIRD-LINE WITH THE 180MG DOSE ((o)) MALIA NYSE American: MAIA THIO-101 (Pivotal Phase 2, ongoing): Overall Survival (3L) * Current data in third-line indicates that as of 15-Jan-2025, 100! — estimated Median Overall Survival (OS) is at 16.9 months Ly with a 95% CI lower bound of 12.
Slide 14: Expected Efficacy in Pivotal Trials in NSCLC 3L
EXPECTED EFFICACY IN PIVO TRIALS IN NSCLC 3L Target Population DCR ORR PFS os THIO-1014 Pivotal Phase 2 THIO + Libtayo® (n = 137-148) THIO-104 Pivotal THIO + CPI (n = 150) Phase 3 Chemotherapy (n = 150) * CPI+ Platinum Resistant|| * CPI + Platinum Resistant * Prior treatment with * Stratified: prior
Slide 15: Other Tumor Types Planned Trials
OTHER TUMOR TYPES PLANNED TRIALS (si) MAIA
Slide 16: THIO-102 Trial (Planned)
THIO-102 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with a Checkpoint Inhibitor (CPI) Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Baskets Umbrella Arms Colorectal Cancer (CRC) Hepatocellular Checkpoint Inh
Slide 17: Colorectal Rationale
COLORECTAL RATIONALE (i) MAIA NYSE American: MAIA 700 —©=Control & 600 —e-Atezolizumab ? = 500 —e—THIO * THIO followed by CPI results in 100% € 400 complete response 3 300 =e THIO'= Alero * Only 2 cycles of therapy were 8 200 administered on weeks 1 and 2; no i 100 a CR further therapy throughout th
Slide 18: SCLC & HCC - Orphan Drug Designation
SCLC & HCC —- ORPHAN DRUG DESIGNATION SCLC —®-Control —e=Pembro > THIO —e—THIO > Pembro Tumor Volume (mm?) a 3 0 5 10 15 20 25 Days After Tumor Inoculation * THIO is synergistic with anti-PD-1 agent Pembrolizumab in ‘Small Cell Lung Carcinoma (H2081) in vivo in humanized murine cancer model * Treatm
Slide 19: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS _~ 6007/-& Control i) * THIO achieved complete and durable responses in E Hepatocellular Carcinoma (HCC), the dominant = 400 histology in primary liver cancer (90%), in in vivo £ models 2 $s ~ 200 2 100% CR 3 = 1 0 0 5 101520 2530354045 Days after tumor inoculation 1
Slide 20: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY (oi * When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated * Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented * Administration of THIO alone and i
Slide 21: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with a Checkpoint Inhibitor (CPI) Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 SCLC First Line THIO lel CPIs: Expand to Immune | ° Opportunity to test Piv
Slide 22: Investment Opportunity
INVESTMENT OPPORTUNITY (si) MAIA
Slide 23: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY() = Goal: New Chemical Entity (NCE) Marketing Exclusivity Lr ¢ THIO has never been previously approved by the FDA for commercialization + Robust exclusivity + US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for THIO * 9 issued
Slide 24: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM <4 Vlad Vitoc, MD, MBA Sergei Gryaznov,PhD Jeffrey Himmelreich, MBA Founder and CEO Chief Scientific Officer Head of Finance + 24+ years in Oncology Pharma/ + 25+ years as Scientist * 20+ years of financial Biotech: Commercial, Medical + Expert Drug Discovery and expertis
Slide 25: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY ~ > Developing agents for the top tumor Checkpoint Inhibitors Market ’ types markets globally saa 8 NSCLC (#1 WW) HcCc Mortality: 1.7M / Sales: $34B Mortality: 0.8M / Sales: $3B 25 25 20 CRC (#2 WW) SCLC Mortality: 1.0M / Sales: $20B | | Mortality: 0.3M / Sales: $2B 15
Slide 26: Comparable Companies
4 2 COMPARABLE COMPANIES ° August 2022 - Bristol Myers Squibb (BMS) completed $4.4B acquisition of Turning Point Therapeutics ° January 2024 - BMS completed $5.8B acquisition of Mirati Therapeutics (hy) MAIA | Bicycle AMARRIVENT /ARCUS @ Turning Point MIRAT| =n THERAPEDTICS $50.6M $0.66B $0.67B $0.9
Slide 27: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES fei) MAIA NYSE American: MAIA 2025 2026 THIO-104. Enrollment Potential Filing for Early Full Approval Ph3 First Patient In in US (from interim analysis) NSCLC 3L * THIO-104 Part C Part B Part C Enrollment Filing for Potential Filing for Ph2 First Full Efficacy Compl
Slide 28: Thank You
MAIA BIOTECHNOLOGY THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 NYSE American: MAIA
Slide 29: Appendix
APPENDIX (si) MAIA
Slide 30: U.S. FDA Granted Orphan Drug Designations and Rare Pediatric Disease Designation to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS AND 1 fyi) MALA RARE PEDIATRIC DISEASE DESIGNATION TO THIO Soper @ THIO has been granted 3 Orphan Drug Designations (ODD): Y Hepatocellular Carcinoma (HCC, 90% of primary liver cancers) ¥ Small Cell Lung Cancer (SCLC, deadliest lung cancer) Y Glioblastoma
MAIA Biotechnology — Investor Presentation (March 2025) on 6ix